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RESEARCH
Effectiveness of icatibant for treatment 
of hereditary angioedema attacks is not affected 
by body weight: findings from the Icatibant 
Outcome Survey, a cohort observational study
Teresa Caballero1,8*, Andrea Zanichelli2, Werner Aberer3, Marcus Maurer4, Hilary J. Longhurst5,9, 
Laurence Bouillet6 and Irmgard Andresen7 on behalf of the IOS Study Group
Abstract 
Background: Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema 
attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body 
mass index (BMI) on the effectiveness of icatibant is not documented in the literature. We examined disease charac-
teristics and icatibant treatment effectiveness in patients stratified by BMI in the Icatibant Outcome Survey, an ongo-
ing, international, observational study monitoring the real-world safety and effectiveness of icatibant.
Methods: Attack and treatment characteristics as well as outcomes following treatment with icatibant were com-
pared among patients with underweight, normal, overweight, and obese BMI.
Results: Data from 2697 icatibant-treated attacks in 342 patients (3.5, 44.7, 34.8, and 17.0% patients of underweight, 
normal, overweight, and obese BMI, respectively) were analyzed. There was no significant difference in the frequency 
and severity of attacks across BMI groups, although obese patients tended to have more attacks of high severity. 
There was no impact of BMI on the frequency of laryngeal attacks, but patients with normal BMI had fewer cutaneous 
attacks and more abdominal attacks. Most attacks (71.9–83.8%) were treated with a single icatibant injection without 
the need for rescue with plasma-derived C1-inhibitor (pdC1-INH), regardless of BMI. Patients with obese BMI used 
pdC1-INH as rescue treatment more often (P < 0.0001; P = 0.0232 excluding 2 outliers) and treated attacks earlier than 
patients with normal BMI (P = 0.007). Furthermore, time to resolution and duration of attack were shorter for patients 
with high BMI (P < 0.001 for overweight and P < 0.05 for obese versus normal).
Conclusion: Overall, icatibant was comparatively effective in treating attacks in patients across all BMI groups.
Trial registration NCT01034969.
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Background
Hereditary angioedema due to C1-inhibitor (C1-INH) 
deficiency (C1-INH-HAE) is a genetic disease, affecting 
one in 50,000 [1] people, with symptoms such as local-
ized cutaneous swelling, abdominal pain, and laryngeal 
edema [2]. C1-INH-HAE is caused by mutations in the 
SERPING1 gene, leading to C1-INH deficiency and sub-
sequently elevated levels of bradykinin, the mediator of 
increased vascular permeability during attacks [1, 3].
Icatibant  (Firazyr®; Shire, Zug, Switzerland) is a subcu-
taneously administered bradykinin B2 receptor antago-
nist that has demonstrated efficacy and safety for the 
treatment of acute attacks of C1-INH-HAE [4, 5]. The 
approved dose of icatibant in patients ≥ 18  years of age 
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is 30 mg, and is based on clinical studies using a dose of 
0.4  mg/kg body weight. Clinical trials did not show an 
impact of body weight on the safety and efficacy of icati-
bant, and dosing is not adjusted by body weight. How-
ever, the effect of body weight on treatment outcomes 
has not been evaluated in the real-world setting. Body 
weight can have an impact on the pharmacokinetics 
and pharmacodynamics of a drug and, subsequently, its 
effectiveness. In addition, the relationship between body 
weight and the characteristics of C1-INH-HAE attacks is 
not known.
The Icatibant Outcome Survey (IOS; NCT01034969) is 
an ongoing international observational study that moni-
tors the safety and effectiveness of treatment with icati-
bant. In this analysis, the relationship between body mass 
index (BMI), attack characteristics, and icatibant treat-
ment outcomes in patients with C1-INH-HAE type I and 
type II receiving icatibant was investigated in the real-
world setting.
Methods
Study design
Details on the design and conduct of IOS are described 
elsewhere [6]. Patients were enrolled from 51 sites in 
11 countries: Brazil, Israel, and across Europe. In this 
analysis, data from icatibant-treated patients with 
C1-INH-HAE type I or II were obtained from patients 
who entered the study between July 2009 and Febru-
ary 2016. Patients were divided into groups according 
to their BMI at baseline (i.e., before enrollment): under-
weight (< 18.5  kg/m2), normal (18.5 to < 25.0  kg/m2), 
overweight (25.0 to < 30.0 kg/m2), or obese (≥ 30 kg/m2). 
Details regarding the characteristics of icatibant-treated 
C1-INH-HAE attacks and the use of any concomitant or 
rescue medications, including C1-INH, were collected 
via physician-completed electronic forms at routine visits 
(recommended every 6 months). Patients were educated 
by their HAE specialist to report attack severity based 
on the extent of interference with daily activities. Attack 
severity was classified as: very mild (very mild interfer-
ence with daily activities); mild (mild interference with 
daily activities); moderate (moderate interference with 
daily activities and no other countermeasures required); 
severe (severe interference with daily activities and with 
or without other countermeasures); or very severe (very 
severe interference with daily activities and other coun-
termeasures required).
Statistical analysis
Due to the small number of patients and attacks in the 
underweight BMI group, statistical comparisons of 
BMI groups did not include the underweight category, 
and the results of the underweight BMI group are only 
summarized descriptively. Statistical testing was con-
sidered exploratory in this observational study and no 
adjustment for multiplicity was performed. There was no 
imputation of data from patients who discontinued from 
the study.
Attack rate and duration of untreated attacks were both 
compared using the Kruskal–Wallis test. Attack severity, 
attack site, and the use of plasma-derived C1-INH as a 
rescue medication in the normal, overweight, and obese 
BMI groups were compared using a generalized linear 
model of repeated measures (PROC GLIMMIX; SAS 
Institute Inc., Cary, NC, USA).
Treatment outcomes included time to treatment (time 
from attack onset to icatibant injection), time to resolu-
tion (time from icatibant injection to complete symptom 
resolution), and attack duration (time from attack onset 
to complete resolution of symptoms). A mixed-model 
analysis of repeated measures (PROC MIXED; SAS 
Institute Inc.) was used to compare mean time to treat-
ment, time to resolution, and duration of attack data 
for patients in the BMI groups using base-10 log-trans-
formed time data (h). The impact of BMI along with sex, 
age (i.e., factors that influence BMI), and other patient 
and attack characteristics on treatment outcomes were 
analyzed using a generalized linear model of repeated 
measures with PROC GENMOD (SAS Institute Inc.). 
A multivariate model was built using a backward selec-
tion process, which incorporated variables from the uni-
variate model with P values < 0.20 and removed factors 
with the highest P values until only significant factors 
remained (P ≤ 0.05). Odds ratios (ORs) and correspond-
ing 95% confidence intervals were estimated.
Results
Patient characteristics
The analysis included data from 2697 icatibant-treated 
attacks reported by 342 patients with C1-INH-HAE 
for whom baseline BMI data were available. Of the 342 
patients, 12 (3.5%), 153 (44.7%), 119 (34.8%), and 58 
(17.0%) had an underweight, normal, overweight, and 
obese BMI, respectively (Table  1). There was a compa-
rable distribution of males and females among patients 
with overweight or obese BMI, but most patients with 
normal or underweight BMI were female. Almost half 
(n = 169; 49.4%) of the patients were using long-term 
prophylaxis. There was no difference among the normal, 
overweight, and obese BMI groups in the type of long-
term prophylaxis therapy used.
Attack characteristics
Among the normal, overweight, and obese BMI groups, 
there was no difference in the mean attack frequency 
per patient during enrollment (P = 0.469). There were 
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more attacks classified as very severe in patients with 
obese BMI (25.9%) than in patients with normal (15.4%) 
or overweight (9.6%) BMI (Fig.  1); however, there were 
no statistically significant differences in attack severity 
within any of the groups (P > 0.1 comparing very mild/
mild/moderate versus severe/very severe attacks).
There were some significant differences in attack site 
frequency among the BMI groups: patients with normal 
BMI had fewer attacks affecting the skin (P = 0.020) and 
more attacks affecting the abdomen (P = 0.003; Fig.  2). 
There was no impact of BMI on the frequency of attacks 
affecting the larynx (P = 0.282).
Table 1 Patient demographics and number of icatibant-treated attacks
BMI body mass index; C1-INH C1-inhibitor; SD standard deviation
a At study entry
b Percentage calculated from number of patients using long-term prophylaxis at study entry and/or during enrollment
c Attack rate during enrollment. P = 0.469 comparing the normal, overweight, and obese categories. The underweight category was excluded from the comparison 
due to small sample size. Two patients (one normal BMI, one obese BMI) were found to be outliers because of an abnormally high rate of reinjections and rescue 
medication use. When their data are excluded, mean ± SD for normal = 8.4 ± 14.6 attacks/patient and for obese = 6.9 ± 8.6 attacks/patient (Additional file 1: Table S1)
Characteristic Underweight BMI Normal BMI Overweight BMI Obese BMI
Patients, n (%) 12 (3.5) 153 (44.7) 119 (34.8) 58 (17.0)
BMI (kg/m2)a
 Mean ± SD 18.0 ± 0.5 22.2 ± 1.8 26.9 ± 1.3 34.5 ± 4.1
 Median (range) 18.1 (16.7–18.4) 22.4 (18.7–25.0) 26.6 (25.0–29.8) 33.3 (30.0–46.7)
Sex, n (%)
 Female 11 (91.7) 105 (68.6) 60 (50.4) 33 (56.9)
 Male 1 (8.3) 48 (31.4) 59 (49.6) 25 (43.1)
Age at enrollment (years), n (%)
 ≥ 12 to < 18 1 (8.3) 2 (1.3) 1 (0.8) 0
 ≥ 18 to < 30 8 (66.7) 53 (34.6) 24 (20.2) 10 (17.2)
 ≥ 30 to < 50 1 (8.3) 66 (43.1) 52 (43.7) 27 (46.6)
 ≥ 50 to < 65 1 (8.3) 27 (17.6) 30 (25.2) 16 (27.6)
 ≥ 65 1 (8.3) 5 (3.3) 12 (10.1) 5 (8.6)
Country, n (%)
 Austria 0 6 (3.9) 3 (2.5) 0
 Brazil 0 6 (3.9) 7 (5.9) 3 (5.2)
 Denmark 0 0 1 (0.8) 2 (3.4)
 France 2 (16.7) 45 (29.4) 21 (17.6) 8 (13.8)
 Germany 2 (16.7) 16 (10.5) 16 (13.4) 12 (20.7)
 Greece 0 3 (2.0) 3 (2.5) 1 (1.7)
 Israel 2 (16.7) 20 (13.1) 15 (12.6) 6 (10.3)
 Italy 1 (8.3) 18 (11.8) 14 (11.8) 4 (6.9)
 Spain 4 (33.3) 20 (13.1) 22 (18.5) 8 (13.8)
 Sweden 0 0 1 (0.8) 0
 United Kingdom 1 (8.3) 19 (12.4) 16 (13.4) 14 (24.1)
Ongoing long-term prophylaxis, n (%)
 n 3 75 58 33
 C1-INHb 0 11 (14.7) 11 (19.0) 4 (12.1)
 Attenuated  androgensb 0 47 (62.7) 44 (75.9) 24 (72.7)
 Tranexamic  acidb 2 (66.7) 24 (32.0) 9 (15.5) 11 (33.3)
 Otherb 1 (33.3) 8 (10.7) 4 (6.9) 3 (9.1)
No. of icatibant-treated attacks during enrollment 104 1314 829 450
No. of icatibant-treated attacks per  patientc
 Mean ± SD 8.7 ± 13.5 8.6 ± 14.8 7.0 ± 11.3 7.8 ± 10.8
 Median (range) 4.0 (1–47) 4.0 (1–101) 3.0 (1–83) 3.5 (1–57)
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The IOS database also captured some information 
on attacks that were untreated. A total of 309 patients 
reported the occurrence of untreated attacks at baseline, 
and 182 patients reported untreated attacks at follow-up 
(Table 2). When we compared the duration of untreated 
attacks across BMI groups, no statistical difference in the 
mean duration of attack among the three BMI groups 
was found (P = 0.408 at baseline, P = 0.530 at follow-up), 
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although mean attack duration at follow-up tended to be 
longer in the obese BMI group.
Treatment characteristics
Icatibant use was comparable among the BMI groups 
(Table  3). More than 70% of icatibant injections among 
all BMI groups were self-administered. Overall, 88.3, 
83.8, 83.2, and 71.9% of attacks in patients with under-
weight, normal, overweight, and obese BMI, respectively, 
were treated with a single icatibant injection and without 
plasma-derived C1-INH rescue medication. Two patients 
(one with normal BMI, one with obese BMI) were pre-
viously identified as outliers because of an abnormally 
high rate of reinjections and rescue medication use [7]. 
Patient characteristics excluding the outliers are pre-
sented in Additional file 1: Table S1. When data from the 
two outliers were excluded, 88.3, 84.6, 83.2, and 82.0% 
of attacks in patients with underweight, normal, over-
weight, and obese BMI, respectively, were treated with a 
single icatibant injection (Additional file  1: Table S3). A 
single dose of plasma-derived C1-INH (pdC1-INH) was 
administered as rescue medication in 8.7, 7.7, 10.9, and 
21.3% of attacks for patients with underweight, normal, 
overweight, and obese BMI, respectively (P < 0.0001). 
In most attacks that were treated with pdC1-INH res-
cue, pdC1-INH was administered following a single 
dose of icatibant. When data from the outliers were 
excluded, pdC1-INH use occurred in 8.7, 7.9, 10.9, and 
12.0% of attacks for patients with underweight, normal, 
overweight, and obese BMI, respectively (P = 0.0232). 
Thus, there was a slight increase in the rate of pdC1-INH 
use with higher BMI.
Treatment outcomes
Overall, there was no difference among the BMI groups 
in time to treatment (P = 0.468; Fig.  3). However, pair-
wise comparisons showed that time to treatment was 
shorter for patients with overweight BMI compared 
with patients with normal BMI (P = 0.007). There were 
significant differences overall among the BMI groups 
with respect to duration of attack and time to resolution 
(P < 0.001 for both outcomes). Moreover, both outcomes 
were significantly shorter for patients with overweight 
and obese BMI compared with patients with normal 
BMI. Time to resolution was significantly extended in 
patients with overweight and obese BMI if they treated 
attacks ≥ 1 or ≥ 2 h after attack onset compared with ear-
lier treatment (Table  4). However, this impact on time 
to resolution was not observed in patients with normal 
BMI.
Multivariate regression analyses showed that patients 
with BMI ≥ 25  kg/m2 were more likely to treat attacks 
within 1 h than patients with BMI < 25 kg/m2 (P < 0.0295; 
Table  5). Patients with a high frequency of attacks also 
were more likely to treat attacks early, and country also 
plays a role in time to treatment in the univariate analysis 
(P < 0.0001), which was not confirmed in the multivariate 
analysis (Table 5). Time to resolution was more likely to 
be shorter for patients with higher BMI, and for attacks 
that were treated with C1-INH rescue medication or that 
affected the skin (Table 6).
Adverse events (AEs)
There was no difference in the rate of AEs between 
patients with underweight, normal, overweight, and obese 
BMI (Table 7). The most common treatment-related AEs 
across all other BMI groups were injection site reactions 
such as injection site pain (one report in one patient with 
overweight BMI) and injection site erythema (six reports 
in one patient with overweight BMI and one report in 
one patient with normal BMI). There were no injection 
site reactions in patients with obese BMI. There were no 
differences between the BMI groups with respect to the 
rate of vascular AEs. Two patients in the overweight BMI 
group reported a total of three serious AEs related to icat-
ibant (gastritis and reflux esophagitis in one patient and 
angioedema in another patient).
Discussion
The results of our analysis of real-world data showed 
that the frequency and characteristics of C1-INH-
HAE attacks are generally similar across BMI groups. 
Table 2 Average duration of untreated attacks
Average duration of untreated attacks corresponds to mean of average 
durations of untreated attacks at the skin, abdomen, larynx, and other sites
BMI body mass index; SD standard deviation; n = the number of patients
a P values comparing average duration of attack at baseline between patients 
with normal/overweight/obese BMI: P = 0.408 at baseline; P = 0.530 at follow-up. 
Results excluding data from the two reinjection outliers are presented in 
Additional file 1: Table S2
Under-
weight BMI
Normal 
BMI
Over-
weight 
BMI
Obese BMI
Baseline
Average duration of attack (h)
 n 12 150 106 41
 Mean ± SDa 50.7 ± 22.9 40.5 ± 32.4 45.9 ± 31.5 44.4 ± 35.5
 Median 
(range)
48.0 (6–92) 41.0 (0–140) 48.0 (0–156) 48.0 (0–120)
Follow-up
Average duration of attack (h)
 n 11 76 70 25
 Mean ± SDa 34.6 ± 21.6 39.7 ± 31.1 37.6 ± 30.6 44.2 ± 29.9
 Median 
(range)
36 (0–72) 37.5 (0–144) 28.7 (0–120) 48.0 (0.3–120)
Page 6 of 10Caballero et al. Clin Transl Allergy  (2018) 8:11 
Interestingly, the rate of attacks according to site sig-
nificantly differed by BMI group in that patients with 
high BMI reported fewer attacks on the abdomen and 
more attacks on the skin. The reason for the difference 
is unknown, but a relationship between BMI and media-
tors of angioedema or inflammation in the gut could be 
possible.
The results of our analysis of real-world observational 
data showed that treatment of C1-INH-HAE attacks with 
icatibant was successful regardless of BMI. The majority 
of attacks across BMI groups were treated with a single 
dose of icatibant and without the need for pdC1-INH 
rescue medication. Although there was a higher rate of 
pdC1-INH rescue medication use in patients with obese 
BMI (even when data from the two outlier patients were 
excluded), the difference between obese and other BMI 
groups was minimal. This suggests that overall, it is not 
necessary to adjust the administered dose of icatibant 
according to body weight.
Data from studies in healthy volunteers showed a 
significant correlation between body weight and the 
clearance and volume of distribution of icatibant, result-
ing in decreased systemic exposure for those with higher 
body weight [8]. This lower exposure could explain why 
there was an apparent increase in the rate of rescue med-
ication use in patients with higher BMI. However, these 
studies were limited to volunteers with BMI < 30  kg/m2, 
thus effects in obese patients are unclear.
Patients with higher BMI were more likely to treat with 
icatibant within 1 h after the onset of an attack, and time 
to resolution and duration of attack were subsequently 
shorter in these patients. However, factors that impact 
BMI such as sex and age did not contribute to this out-
come. The early treatment observed in overweight and 
obese BMI patients could be attributed to higher attack 
severity in these patients, or to the longer time required 
for attack resolution with delayed treatment in these 
groups. Earlier treatment and higher severity may sug-
gest a more rapid onset of attacks in obese BMI patients, 
or conversely, a greater perception of symptoms leading 
to earlier treatment.
Table 3 Treatment of attacks
BMI body mass index; C1-INH C1-inhibitor; HCP health care provider; SD standard deviation; n = number of attacks, excluding attacks with missing or unknown data
a Two patients (one normal BMI, one obese BMI) were found to be outliers because of an abnormally high rate of reinjections and rescue medication use. However, 
their data were included in this analysis
b One patient experienced an abdominal attack that lasted for 6 days; the patient was treated with one icatibant injection each day, for a total of six injections
c When data from the outlier patient were excluded, 47/393 (12.0%) of attacks were treated with C1-INH. The other outlier patient did not use any rescue medication 
(Additional file 1: Table S3)
d One attack was treated with C1-INH; however, the number of icatibant injections used was unknown
Underweight BMI Normal BMI Overweight BMI Obese BMI
Type of administration, n (%)a
 n 103 1261 792 415
 HCP 10 (9.7) 367 (29.1) 148 (18.7) 67 (16.1)
 Self 93 (90.3) 894 (70.9) 644 (81.3) 348 (83.9)
No. of icatibant injections per  attacka
 n 103 1301 826 434
 Mean ± SD 1.0 ± 0.2 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.4
 Median (range) 1 (1–3) 1 (1–3) 1 (1–3) 1 (1–6)
No. of icatibant injections per attack, n (%)a
 n 103 1301 826 434
 1 91 (88.3) 1090 (83.8) 687 (83.2) 312 (71.9)
 1 + C1-INH rescue medication 9 (8.7) 83 (6.4) 85 (10.3) 73 (16.8)
 2 2 (1.9) 112 (8.6) 48 (5.8) 24 (5.6)
 2 + C1-INH rescue medication 0 8 (0.6) 5 (0.6) 22 (5.1)
 3 1 (1.0) 6 (0.5) 1 (0.1) 2 (0.5)
 3 + C1-INH rescue medication 0 2 (0.2) 0 0
 6 0 0 0 1 (0.2)b
C1-INH rescue medication, n (%)
 n 104 1314 829 450
 No. of attacks used C1-INH rescue 9 (8.7) 101 (7.7)c 90 (10.9) 96 (21.3)c,d
 No. of patients used C1-INH rescue 2 29 21 16
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Fig. 3 Outcomes of attacks treated with icatibant by body mass index (BMI). Analysis included attacks with data for all three outcomes. Boxes 
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The results of the analysis presented here should be 
considered in the context that this was a retrospective 
analysis of real-world data rather than a randomized con-
trolled clinical trial examining differences in the effec-
tiveness of icatibant in patients with low or high BMI. 
Over half of the patients in this analysis had overweight 
or obese BMI, however this was similar to the overall dis-
tribution of BMI for adults in Europe [9]. Data collection 
was dependent on patient compliance with accurately 
documenting their attacks and treatments. In addition, 
the data collected on untreated attacks or attacks treated 
with other drugs were not as detailed as the data col-
lected for icatibant-treated attacks. Thus, we were unable 
to fully evaluate the severity of disease in patients in the 
three BMI groups, as it is possible that not all attacks 
were accounted for.
Table 4 Impact of time to treatment on mean time to resolution and duration of attack
Results excluding the two outlier patients are presented in Additional file 1: Table S4
BMI body mass index; n.a. not applicable; statistical comparison was not conducted due to small sample sizes; SD standard deviation; n = the number of attacks
Time to treatment n Underweight BMI n Normal BMI n Overweight BMI n Obese BMI
Mean ± SD time to resolution
 0 to < 1 h 6 15.6 ± 16.7 155 10.4 ± 12.5 148 7.9 ± 11.0 108 5.4 ± 9.5
 ≥ 1 h 6 10.1 ± 8.4 253 15.0 ± 17.7 201 9.9 ± 12.4 106 15.0 ± 17.4
 P value n.a. 0.078 0.001 < 0.001
 0 to < 2 h 6 15.6 ± 16.7 228 11.8 ± 13.5 193 8.4 ± 12.0 142 6.5 ± 10.1
 ≥ 2 h 6 10.1 ± 8.4 180 15.0 ± 18.6 156 9.8 ± 11.6 72 17.5 ± 19.2
 P value n.a. 0.734 0.011 < 0.001
Mean ± SD duration of attack
 0 to < 1 h 6 15.8 ± 16.7 155 10.7 ± 12.5 148 8.1 ± 11.0 108 5.6 ± 9.5
 ≥ 1 h 6 18.7 ± 12.5 253 21.8 ± 22.0 201 14.8 ± 14.2 106 22.4 ± 20.8
 P value n.a. < 0.001 < 0.001 < 0.001
 0 to < 2 h 6 15.8 ± 16.7 228 12.3 ± 13.7 193 8.9 ± 12.1 142 6.9 ± 10.2
 ≥ 2 h 6 18.7 ± 12.5 180 24.2 ± 23.8 156 15.8 ± 13.9 72 27.7 ± 22.1
 P value n.a. < 0.001 < 0.001 < 0.001
Table 5 Evaluation of factors affecting time to  treatmenta
BMI body mass index; CI confidence interval; HCP health care provider
a Model of probability that time to treatment < 1 h
b Only effects with P < 0.2 are shown. Complete results are presented in 
Additional file 1: Table S5
c Overall effect of country on time to treatment
d Only significant effects are shown
e Results were similar when data from the two reinjection outliers were 
excluded (Additional file 1: Table S6)
Effect (numerator) Odds ratio 95% CI P value
Univariate  analysisb
 Attack frequency (≥ 10 attacks/
year)
2.48 – < 0.001
 BMI (≥ 25 kg/m2) 1.77 – 0.012
 Type of administration (HCP) 0.55 – 0.067
 Country < 0.0001c
Multivariate  analysisd
 Attack frequency (≥ 10 attacks/
year)e
2.89 1.36–6.14 0.0056
 BMI (≥ 25 kg/m2)e 1.71 1.06–2.79 0.0295
Table 6 Evaluation of factors affecting time to  resolutiona
BMI body mass index; C1-INH C1-inhibitor; CI confidence interval; HCP health 
care provider
a Model of probability that time to resolution < 5 h
b Only effects with P < 0.2 are shown. Complete results are presented in 
Additional file 1: Table S7
c Overall effect of country on time to resolution
d Only significant effects are shown. Complete results excluding the two 
reinjection outliers are presented in Additional file 1: Table S8
Effect (numerator) Odds ratio 95% CI P value
Univariate  analysisb
 BMI (≥ 25 kg/m2) 1.52 – 0.072
 C1-INH rescue medication (yes) 0.66 – 0.097
 Affected site: skin (yes) 0.74 – 0.118
 Type of administration (HCP) 1.49 – 0.133
 Time to first injection (≥ 1 h) 0.78 – 0.142
 Country 0.019c
Multivariate  analysisd
 BMI (≥ 25 kg/m2) 4.46 2.24–8.89 < 0.0001
 C1-INH rescue medication (yes) 0.31 0.19–0.50 < 0.0001
 Affected site: skin (yes) 0.65 0.43–1.00 0.049
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Conclusions
In conclusion, icatibant was well tolerated and used suc-
cessfully to treat attacks in patients with overweight and 
obese BMI.
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